Japan's Ono pays $2.4B for Qinlock-maker Deciphera as biotech readies another approval run Japan’s Ono Pharmaceutical is picking up Deciphera Pharmaceuticals for $2.4 billion, a price tag that brings both the approved cancer drug Qinlock and another candidate heading to the FDA’s desk in the coming months. Log in or register to post comments
